



Enhanced expression of the central survival of motor neuron (SMN) protein during the pathogenesis of osteoarthritis

Citation

Cucchiari, Magali, Henning Madry, and Ernest F Terwilliger. 2014. "Enhanced expression of the central survival of motor neuron (SMN) protein during the pathogenesis of osteoarthritis." *Journal of Cellular and Molecular Medicine* 18 (1): 115-124. doi:10.1111/jcmm.12170. <http://dx.doi.org/10.1111/jcmm.12170>.

Published Version

doi:10.1111/jcmm.12170

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581238>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Enhanced expression of the survival of motor neuron (SMN) protein during the pathogenesis of osteoarthritis

Magali Cucchiari ^{a, *}, Henning Madry ^{a, b}, Ernest F. Terwilliger ^c

^a Center of Experimental Orthopaedics, Saarland University Medical Center, Homburg/Saar, Germany

^b Department of Orthopaedics and Orthopaedic Surgery, Saarland University Medical Center, Homburg/Saar, Germany

^c Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Received: May 24, 2013; Accepted: September 19, 2013

Abstract

The identification of new components implicated in the pathogenesis of osteoarthritis (OA) might improve our understanding of the disease process. Here, we investigated the levels of the survival of motor neuron (SMN) expression in OA cartilage considering the fundamental role of the SMN protein in cell survival and its involvement in other stress-associated pathologies. We report that SMN expression is up-regulated in human OA compared with normal cartilage, showing a strong correlation with the disease severity, a result confirmed *in vivo* in an experimental model of the disease. We further show that the prominent inflammatory cytokines (IL-1 β , TNF- α) are critical inducers of SMN expression. This is in marked contrast with the reported impaired levels of SMN in spinal muscular atrophy, a single inherited neuromuscular disorder characterized by mutations in the *smn* gene whereas OA is a complex disease with multiple aetiologies. While the precise functions of SMN during OA remain to be elucidated, the conclusions of this study shed light on a novel pathophysiological pathway involved in the progression of OA, potentially offering new targets for therapy.

Keywords: osteoarthritis progression • pro-inflammatory cytokines • SMN expression

Introduction

Osteoarthritis (OA) is a degenerative disease of the whole joint [1] that affects millions of people worldwide. Osteoarthritis is mainly characterized by a slow, progressive destruction of major components of the extracellular cartilage matrix, resulting from a disturbed balance of physiological processes in chondrocytes [2], the unique cartilage-forming cells. Various risk factors have been associated with the incidence of OA (genetic background, ageing, trauma, obesity and metabolic conditions) [3–6]. Several lines of evidence have demonstrated the critical involvement of stress stimuli in the pathogenesis of OA, including mechanical stress (loading), oxidative and biochemical stress (production of nitric oxide and of reactive oxygen species; release of cartilage matrix degradation products, of pro-inflammatory cytokines like the prominent interleukin 1 beta - IL-1 β and tumour

necrosis factor alpha - TNF- α , and of matrix-degrading enzymes) [7, 8]. It is well accepted that chondrocytes are key players in the initiation and progression of OA. In normal adult cartilage, they are terminally differentiated cells showing basically no proliferative activity and maintaining the matrix components (proteoglycans, type-II collagen) under low turnover. In early OA, the chondrocyte undergo significant changes in their gene expression profiles (including through epigenetic modifications) [9, 10], leading to transient proliferative responses and to the synthesis of molecules that are not naturally present in the adult cartilage (type-X, type-III, type-VI, and type-IIA collagen, tenascin, decorin) while stopping to express the major matrix components [10, 11]. This has been seen as an attempt at repair but that is eventually counterbalanced by the activation of stress pathways and molecules, by a decline in the cell responsiveness to reparative stimuli, and by cell senescence and degeneration, leading to an irreversible deterioration of the cartilage architecture [12].

Despite recent, critical advances in the identification of OA-related biomarkers that might allow for rapid and effective early OA diagnosis (and for a potential development of beneficial treatment options) [13, 14], the pathophysiology of this complex disorder is not yet fully understood [15–17], showing the need to explore new aspects or

*Correspondence to: Magali CUCCHIARINI, Ph.D.,
Center of Experimental Orthopaedics,
Saarland University Medical Center,
Kirrbergerstr. Bldg 37, Homburg/Saar D-66421, Germany.
Tel.: +49-6841-1624-987
Fax: +49-6841-1624-988
E-mail: mmccucchiarini@hotmail.com

components of the disease that might define new targets for therapy. As chondrocytes are subjected to various stress stimuli in the OA joint, we investigated the expression profiles of the *survival of motor neuron (smn)* gene in the cartilage during the course of OA in light of the response of the SMN product to stress conditions (environmental stress, heat shock and irradiation) by accumulation of the molecule in stress granules [18] and its significant role in oxidative stress [18–20]. Survival of motor neuron is a central, ubiquitously expressed protein part of macromolecular complexes, that is of fundamental importance for the survival of all eukaryotic cells [21] and displaying housekeeping functions in RNA metabolism (biogenesis of RNA-protein complexes, pre-mRNA splicing) [22]. For the first time, we report that the levels of SMN are up-regulated in human OA compared with normal adult cartilage, showing a strong correlation with the disease severity and an influence of key OA mediators (IL-1 β and TNF- α), an observation confirmed by analysing the SMN levels in a model of experimentally induced OA *in vivo*. As SMN has further been reported for its anti-apoptotic activities [23] and its influence on transcriptional and post-transcriptional gene regulation [24, 25], all processes relevant of the pathogenesis of OA [12, 26, 27], active work is ongoing to gain insights into the specific roles of differential SMN cartilage expression in OA cartilage and to address the question whether SMN up-regulation is a protective response or is causally involved in this disease.

Materials and methods

Reagents and antibodies

All reagents were from Sigma-Aldrich (Munich, Germany) unless otherwise indicated. The recombinant human IL-1 β and human TNF- α were purchased at R&D Systems (Wiesbaden-Nordenstadt, Germany). The anti-SMN antibodies (H-195 and 2B1) were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).

Subjects and chondrocyte culture

Normal human adult articular cartilage was obtained from unaffected knee joints of patients ($n = 13$; ages 67–72) that underwent tumour surgery. Osteoarthritic cartilage was obtained from the joints of patients ($n = 52$; ages 65–78) undergoing total knee arthroplasty. All patients were from the Department of Orthopaedics and Orthopaedic Surgery of the Saarland University Medical Center, Homburg, Germany. The study was approved by the Ethics Committee of the Saarland Physicians Council. All patients provided informed consent before inclusion in the study. Research was in compliance with the World Medical Association Declaration of Helsinki. Cartilage explants (6.2-mm diameter) and articular chondrocytes were prepared and isolated immediately after collection as previously described [28]. Explants and cells were cultured in DMEM, 50 μ g/ml ascorbic acid, 100 U/ml penicillin G, 100 μ l/ml streptomycin containing 10% foetal bovine serum (FBS) in a humidified atmosphere with 10% CO₂ at 37°C. Cells were tested after only one passage in culture to avoid the shift in chondrocyte phenotype. Some parts of all the normal cartilage explants as well as cells

freshly isolated from this explants were also incubated with IL-1 β or TNF- α (each at a concentration of 10 or 100 ng/ml) for 10 days at 37°C with 10% CO₂, with medium change every 3 days for further analyses.

Animals and experimental osteoarthritis

Thirteen mature chinchilla bastard rabbits (3.5 \pm 0.5 kg weight, 7–8 months old, with closed epiphyses and absence of joint pathology; Charles River, Sulzfeld, Germany) were employed for the study. All procedures were approved by the Saarland University Animal Committee according to German guidelines. Seven rabbits underwent surgical anterior cruciate ligament transection (ACLT) to induce experimental OA lesions in the knee joint cartilage. Using a medial parapatellar approach, the patella was dislocated laterally and the knee placed in full flexion. The ACL was exposed and transected with a #15 scalpel blade. Complete transection was confirmed by a positive intra-operative Lachman test. The incisions were then closed in layers. Post-operatively, the rabbits were allowed normal cage activity without immobilization. Six other rabbits that were sham operated (arthrotomy only) served as controls. The femorotibial joints of the thirteen animals were removed 4 weeks after surgery [29] for further analyses. Isolation of articular chondrocytes was also performed as described above.

Histological analysis

Cartilage explants were processed and paraffin-embedded sections (5 μ m) were stained with safranin O to detect proteoglycans and with haematoxylin and eosin to detect cells [28]. The severity of OA changes was histomorphologically graded on safranin O/haematoxylin and eosin-stained sections using the scoring method described by Mankin *et al.* [30]. This grading system is based on a semi-quantitative evaluation of the cartilage as follows: structure (0: normal; 1: surface irregularities; 2: pannus and surface irregularities; 3: clefts to the transitional zone; 4: clefts to the radial zone; 5: clefts to the calcified zone; 6: complete disorganization), cells (0: normal; 1: diffuse hypercellularity; 2: cloning; 3: hypocellularity), safranin O staining (0: normal; 1: slight reduction; 2: moderate reduction; 3: severe reduction; 4: no dye noted) and tidemark integrity (0: intact; 1: crossed by blood vessels).

Immunohistochemical, immunocytochemical and histomorphometric analyses

The SMN protein was detected on histological sections of cartilage using specific antibodies, a biotinylated secondary antibody (Vector Laboratories, Grünberg, Germany), and the avidin-biotin-peroxidase method (Vector Laboratories) with diaminobenzidine as the chromogen [28]. To control for secondary IgGs, sections were processed with omission of the primary antibody. Samples were examined under light microscopy (BX45 microscope; Olympus, Hamburg, Germany). The percentage of cells positive for SMN immunoreactivity were measured at three standardized sites or using 10 serial immunohistochemical sections for each parameter, test and replicate condition. Analysis programs included SIS Analysis (Olympus), Adobe Photoshop (Adobe Systems, Unterschleißheim, Germany) and Scion Image (Scion Corporation, Frederick, MD, USA). For immunocytochemical analyses, freshly isolated chondrocytes

(2×10^4) were fixed, incubated with anti-SMN antibodies and a Texas-Red-conjugated secondary antibody (Vector Laboratories) [28]. To control for secondary IgGs, cells were processed with omission of the primary antibody. Fluorescence was examined under a fluorescent microscope (CKX41; Olympus) using a 580-nm filter.

Biochemical analyses of the SMN protein

All cartilage explants were processed and analysed for Western blotting analyses as previously described using 50 µg proteins [28]. Expression was revealed with specific antibodies, horseradish peroxidase-labelled secondary antibodies (Vector Laboratories), and the ECL Advance Western blotting detection kit (Amersham Biosciences, Freiburg, Germany). The SMN contents in freshly isolated chondrocytes were measured by an SMN immunoassay as described by Kolb *et al.* [31] with minor modifications. Briefly, chondrocytes (10^4) were adhered to the bottom of the wells of 96-well plates, fixed, permeabilized with 0.1% Triton and blocked with 20% FBS. The anti-SMN 2B1 antibody (1:500) was incubated and bound antibodies were detected using a peroxidase-conjugated antibody (Vector Laboratories) and the Supersignal ELISA Femto Maximum Sensitivity Substrate (Pierce, Bonn, Germany). The luminescent intensity was measured using a GENios spectrophotometer/fluorometer (Tecan, Crailsheim, Germany). Signal background was determined for each sample by omitting the primary antibody. A recombinant SMN protein (Abnova, Taipei City, Taiwan) was employed to generate a standard curve.

Isolation of RNA, cDNA synthesis and real-time RT-PCR

RNA was prepared from all freshly isolated chondrocytes (10^6) using the RNeasy Protect Mini Kit (Qiagen GmbH, Hilden, Germany) with an 'on-column' DNase digestion. Quantification of the RNA concentrations was performed by spectrophotometry; 1 µg RNA was converted to cDNA using the 1st Strand cDNA Synthesis Kit for RT-PCR/AMV (Roche Applied Science, Mannheim, Germany) exactly according to the manufacturer's instructions. Real-time RT-PCR was performed with 2 µl cDNA with the Brilliant SYBR Green QPCR Master Mix (Stratagene - Agilent, Waldbronn, Germany) to detect the transcripts for SMN (forward primer 5'-AAAAGAAGGAAGGTGCTCACATTC-3' and reverse primer 5'-TGGTGTCAATTTAGTGCTGCTCTATG-3'), type-II collagen (forward primer 5'-GGACTTTTCTCCCTCTCT-3' and reverse primer 5'-GACCCGAAGGTCTTACAGGA-3'), and GAPDH for normalization (forward primer 5'-GAAAGGTGAAGGTCGGAGTC-3' and reverse primer 5'-GAAGATGGTGATGGATTTC-3') (all primers at 150 nM; Invitrogen GmbH, Karlsruhe, Germany) [32, 33]. The reaction was carried out on a Mx3000P[®] QPCR System (Stratagene) for 10 min. 95°C, 40 × [30 sec. 95°C, 1 min. 55°C, 30 sec. 72°C], 1 min. 95°C, and 30 sec. 55°C. The end products were examined by gel electrophoresis. Results were captured using the MxPro[™] QPCR Software (Stratagene).

Statistical analysis

Data are expressed as mean ± SD. All human and rabbit cartilage samples were evaluated for the experiments *in situ* and *in vitro*. Data were

obtained by two individuals who were blinded with regard to the groups. The *t*-test and Mann-Whitney Rank Sum Test were employed where appropriate. Statistical analysis was performed with the SPSS software (SPSS Inc./IBM, Chicago, IL, USA). *P* values < 0.05 were considered statistically significant.

Results

SMN expression levels increase in human OA cartilage, correlating with the disease severity

The cohort of OA patients included in the study was divided into three groups based on a histomorphometric score established by Mankin *et al.* [30] for the semi-quantitative estimation of OA extent on safranin O-stained histological cartilage sections (Fig. 1A). Accordingly, significant differences could be observed between these three groups and compared with normal donors (always $P \leq 0.001$; Fig. 1B).

An immunohistochemical analysis of SMN was performed (Fig. 1C) to estimate the percentages of cells reactive for intracellular SMN in all the samples (Fig. 1D). Specific immunoreactivity was seen both in the superficial and middle zones of the cartilage. Significant increases in the levels of SMN protein were noted both in mild (up to 9.1-fold), moderate (up to 10.1-fold) and severe OA (up to 11.1-fold) relative to normal cartilage (always $P \leq 0.001$). Also, the levels of SMN protein significantly increased in moderate (up to 1.5-fold) and severe OA (up to 1.6-fold) *versus* mild OA cartilage (always $P \leq 0.001$) and in severe compared with moderate OA cartilage (up to 1.6-fold, $P \leq 0.001$). When the percentages of SMN-positive cells (Fig. 1D) were combined with the corresponding, individual histological scores per donor or patient (Fig. 1B), a strong correlation was observed between the levels of SMN protein and the disease severity ($R^2 = 0.7215$ when including normal and OA cartilage, $R^2 = 0.7117$ with only OA cartilage, always $P \leq 0.001$; Fig. 2A).

A Western blotting analysis of protein extracts using all the normal and OA cartilage samples demonstrated a single band of about 38 kD corresponding to the SMN protein [22, 34] (Fig. 2B for representative results). In good agreement with the findings of the immunohistochemical analysis, the intensity of the SMN band was always more intense in OA relative to normal cartilage (about 1.5-, 1.6- and 5-fold difference in mild, moderate and severe OA cartilage, respectively) and increased with the disease severity (about 1.1- and 3.3-fold in moderate and severe OA *versus* mild OA, respectively and about 3.1-fold in severe compared with moderate OA).

Quantitative estimation of the amounts of SMN protein by ELISA using freshly isolated normal and OA chondrocytes from all the samples revealed a significant increase in the SMN concentrations both in mild (1.5-fold, $P = 0.045$), moderate (3.4-fold, $P \leq 0.001$) and severe OA (6.4-fold, $P = 0.002$) relative to normal cartilage (Fig. 2C). Again, the amounts of SMN significantly increased in moderate (2.3-fold) and severe OA (4.3-fold) *versus* mild OA cartilage (always $P \leq 0.001$) and in severe compared with moderate OA cartilage (1.9-fold, $P \leq 0.001$).




Fig. 1 Histological grading and survival of motor neuron (SMN) expression in human normal and osteoarthritis (OA) cartilage. All samples were processed for the analysis. **(A)** Safranin O staining of sections from cartilage explants (representative samples; magnification $\times 4$). **(B)** Grading of OA severity on safranin O-stained histological sections from all individual explants (normal donors, $n = 13$, Mankin score 0–2; mild OA patients, $n = 14$, Mankin score 2–4; moderate OA patients, $n = 22$, Mankin score 5–8; severe OA patients, $n = 16$, Mankin score 9–14). **(C)** SMN-specific immunoreactivity on histological sections from cartilage explants (representative samples; magnification $\times 10$). **(D)** Percentages of SMN-positive cells on immunohistochemical sections from all individual explants (8.8–14.5%, 57.6–77.0%, 59.6–85.1% and 83.3–94.5% in normal, mild, moderate and severe OA samples, respectively). *Statistically significant difference between groups.




Fig. 2 Correlation and biochemical analyses. (A) All individual values of (Fig. 1B and D) were combined to evaluate the correlation between the two parameters. (B) Western blotting analysis in human normal and osteoarthritis (OA) cartilage (1: normal cartilage, 2: mild OA, 3: moderate OA, 4: severe OA; representative samples). (C) Survival of motor neuron concentrations in freshly isolated human normal and OA chondrocytes from all the samples (0.08 ± 0.02 , 0.11 ± 0.02 , 0.26 ± 0.07 and 0.52 ± 0.06 ng/mg total proteins in normal, mild, moderate and severe OA samples, respectively). *Statistically significant difference between groups.

Increased abundance of SMN-specific bodies in human OA chondrocytes

An immunocytochemical analysis in freshly isolated normal and OA chondrocytes from all the samples further revealed that the SMN pro-

tein was present in discrete structures (Fig. 3A), consistent with previous reports identifying SMN as part of macromolecular structures (gems) in distinct cell types (muscle, spinal cord and CNS tissue, muscle, skin fibroblasts) [34, 35]. An estimation of the abundance of such SMN-specific bodies showed that the amounts of structures per cell significantly increased both in mild (threefold, $P \leq 0.001$), moderate (fivefold, $P \leq 0.001$) and severe OA (13-fold, $P = 0.002$) relative to normal cartilage (Fig. 3B). Again, the abundance of these structures significantly increased in moderate (1.7-fold) and severe OA (4.3-fold) versus mild OA cartilage (always $P \leq 0.001$) and in severe compared with moderate OA cartilage (2.5-fold, $P \leq 0.001$). When the abundance of SMN-specific bodies (shown on Fig. 3B) were combined with the corresponding, individual histological scores per donor or patient (shown on Fig. 1B), a strong correlation was observed between the amounts of structures and the disease severity of ($R^2 = 0.8952$ when including normal and OA cartilage, $R^2 = 0.8684$ with only OA cartilage, always $P \leq 0.001$; Fig. 3C).

Increased SMN mRNA levels in human OA chondrocytes

Furthermore, SMN mRNA expression was next evaluated by real-time RT-PCR analysis in cellular extracts from all freshly isolated normal and OA chondrocytes of the samples. In agreement with the findings on the protein, the levels of SMN mRNA expression increased with the disease severity and relative to normal cartilage (Fig. 3D). Accordingly, a significant increase in the intracellular ratios was noted both in mild (up to 1.09-fold, $P = 0.005$), moderate (up to 1.14-fold, $P = 0.001$) and severe OA (up to 1.18-fold, $P \leq 0.001$) versus normal cartilage. Also, the ratios significantly increased in moderate (up to 1.07-fold, $P = 0.016$) and severe OA (up to 1.11-fold, $P \leq 0.001$) compared with mild OA cartilage and in severe relative to moderate OA cartilage (up to 1.09-fold, $P = 0.033$). For comparison, the intracellular type-II collagen/GAPDH ratios were also analysed, showing a significant up-regulation with the extent of OA and versus normal cartilage (Fig. 3D), possibly because of an equilibration of the phenotype in the cell in contrast with the situation in the extracellular matrix compartment. A significant increase in the ratios was noted both in mild (up to 1.12-fold), moderate (up to 1.20-fold) and severe OA (up to 1.24-fold) compared with normal cartilage (always $P \leq 0.001$). Also, the ratios significantly increased in moderate (up to 1.09-fold) and severe OA (up to 1.13-fold) relative to mild OA cartilage (always $P \leq 0.001$) and in severe versus moderate OA cartilage (up to 1.05-fold, $P = 0.002$). Yet, the levels of SMN mRNA expression and fold increases noted during OA progression did not reach those attained for type-II collagen (always $P \leq 0.001$).

Effects of IL-1 β and TNF- α upon cartilage SMN expression

As IL-1 β and TNF- α have been described as key mediators of OA, we examined whether application of these cytokines induces detectable




Fig. 3 Molecular analyses. All the samples were processed for the analyses. **(A)** Survival of motor neuron (SMN)-specific immunoreactivity (representative samples; normal chondrocytes are also shown in regular light; magnification $\times 200$). **(B)** Abundance of SMN-specific bodies. **(C)** Correlation between the abundance of SMN-specific bodies and osteoarthritis (OA) severity. The values of Figures 1B and 3B were combined to evaluate the correlation between the two parameters. *Statistically significant difference between groups. **(D)** Normalized mRNA expression of SMN (1.17–1.22, 1.24–1.27, 1.27–1.33 and 1.32–1.38 in normal, mild, moderate and severe OA samples, respectively) and type-II collagen (1.57–1.59, 1.72–1.76, 1.84–1.88 and 1.91–1.94 in normal, mild, moderate and severe OA samples, respectively). Statistically significant difference between groups for *SMN and *type-II collagen.

changes in the SMN immunoreactivity (%) expression profiles of human normal cartilage and freshly isolated chondrocytes (Fig. 4A and C). Treatment with IL-1 β or TNF- α significantly increased the levels of SMN protein compared with normal cartilage (between 4.9- and 7.3-fold, always $P \leq 0.001$) in a dose-dependent manner (1.2- or 1.5-fold increase with IL-1 β or TNF- α from 10 to 100 ng/ml, always $P \leq 0.001$), reaching the levels noted in mild OA when using concentrations of 10 ng/ml and those of moderate OA at 100 ng/ml. An estimation of the amounts of protein in freshly isolated chondrocytes by ELISA further showed significant, dose-dependent increases in the SMN concentrations when providing IL-1 β or TNF- α at 10–100 ng/ml relative to normal, untreated cells (between 1.4- and 2.3-fold difference to the normal condition and an up to 1.6-fold increase depending on the dose, always $P \leq 0.001$; Fig. 4D). The histological analysis of safranin O-stained sections confirmed the effects of both cytokines on cartilage matrix degradation (Fig. 4B).

Differential SMN expression in experimental OA

Survival of motor neuron expression was next investigated in an *in vivo* model of OA induced by ACLT in rabbits to substantiate the results of the analysis in human articular cartilage. Four weeks after ACLT, all knees demonstrated degenerative changes on histological sections of the articular cartilage of the femoral condyles, patellar grooves and tibial plateaus *versus* normal articular cartilage from sham-operated animals (Fig. 5A) [30], in good agreement with previous findings showing that OA changes occur rapidly in this model (within 3–8 weeks) [29]. The extent of OA in rabbit articular cartilage (Mankin score 5–6) was comparable to a moderate OA in human articular cartilage. Accordingly, the scores attributed to rabbit OA cartilage were significantly higher than those of normal rabbit cartilage (Mankin score 0–1; $P = 0.001$; Fig. 5A).





Fig. 4 Effects of IL-1 β and TNF- α upon the survival of motor neuron (SMN) expression levels in human cartilage and chondrocytes. All human normal cartilage explants and cells freshly isolated from these explants were treated for 10 days with either IL-1 β or TNF- α (each at either 10 or 100 ng/ml) and processed as described in the Materials and Methods. Explants and cells defined with severe osteoarthritis (OA) were used as positive controls. **(A)** SMN-specific immunoreactivity on histological explant sections (representative samples; magnification $\times 2$). **(B)** Safranin O staining of histological explant sections (representative samples; magnification $\times 20$). **(C)** Percentages of SMN-positive cells on immunohistochemical explant sections (all samples were processed for the analysis) (normal samples: 9.1–12.7% raising at 60.2–63.1%, 73.4–76.8%, 50.8–53.4% and 77.4–78.6% with IL-1 β or TNF- α at 10 or 100 ng/ml, respectively; severe OA samples: 84.1–86.4%). **(D)** SMN concentrations in freshly isolated chondrocytes (all samples were processed for the analysis) (normal samples: 0.10 ± 0.01 ng/mg total proteins raising at 0.18 ± 0.01 , 0.22 ± 0.02 , 0.14 ± 0.01 and 0.23 ± 0.01 ng/mg total proteins with IL-1 β or TNF- α at 10 or 100 ng/ml; severe OA samples: 0.47 ± 0.01 ng/mg total proteins). *Statistically significant difference between groups.



As noted for human cartilage, the percentages of cells immunoreactive for SMN in rabbit OA cartilage were significantly higher than those in normal rabbit cartilage (up to 11.8-fold; $P \leq 0.001$; Fig. 5B). When these percentages were combined with the corresponding histomorphometric score per animal, a strong correlation was observed between the levels of SMN immunoreactivity and the extent of experimental OA ($R^2 = 0.9808$, $P \leq 0.001$) (Fig. 5C). Western blotting analysis of protein extracts from rabbit cartilage demonstrated a specific band of about 38 kD similar to that detected in human cartilage [22, 34] (Fig. 5D) and that was more intense in rabbit OA cartilage compared with normal rabbit cartilage (about twofold as for moderate human OA). Quantitative estimation of the SMN protein in freshly isolated chondrocytes by ELISA showed a significant increase in the SMN concentrations in rabbit OA cartilage relative to normal rabbit cartilage (3.7-fold, $P \leq 0.001$; Fig. 5D), as noted in moderate human OA.

Discussion

Osteoarthritis is one of the most common disabling human conditions that affects the whole joint, leading to an irreversible destruction of the articular cartilage structure and extracellular matrix. Evidence has accumulated that the chondrocytes, the unique cartilage-forming

cells, play central roles in the disease process, undergoing multiple changes in their gene expression profiles [9, 10] in response to a variety of stress stimuli (loading, inflammation, oxidative stress) [7, 8]. Despite the identification of various biomarkers of the disease, there is a need to better characterize the key cellular and molecular mechanisms that govern the initiation and progression of OA, as the pathophysiology of this complex disorder remains poorly understood. In this study, we specifically examined the expression patterns of the product of the *smn* gene in OA cartilage in light of the implication of SMN in stress-activated pathways [18–20] that are also observed during the OA disease.

For the first time to our best knowledge, we demonstrate that the essential 38-kD cellular SMN protein is expressed both in human normal and OA cartilage in the form of discrete bodies, as previously reported in other tissues [34, 35]. Most remarkably, we provide evidence showing significant increases in the SMN levels in human OA *versus* normal adult cartilage, strongly correlating with the extent of the disease, a result corroborated by findings *in vivo* in a relevant model of experimental OA, suggesting a central, common role of SMN between species and confirming its importance during OA. Interestingly, while modest increases were noted at the mRNA level, more robust effects were observed at the protein level, possibly related to a build up of the protein by post-translational modifications [36]. Work is ongoing to analyse the profiles of SMN in other tissues

relevant of the pathogenesis of OA (synovium, subchondral bone, bone marrow compartment). Finally, we also demonstrate a dose-dependent up-regulation of the SMN levels in the presence of IL-1 β and TNF- α , two prominent stress cytokines and critical mediators of the disease pathogenesis. As a matter of fact, a number of *cis*-elements responsive to disease-associated cytokines (IL-6, interferons beta and gamma - IFN- β and - γ) have been already identified in the promoter region of the *smn* gene [37], supporting the concept of SMN induction under OA-specific biochemical stress. Yet, other mediators that might also influence SMN expression should not be excluded (mechanical and oxidative stress, adipokines, epigenetics) [9, 38, 39], being currently under active investigation. Nevertheless, this study provides strong evidence of the significance of SMN regulation in OA in human damaged cartilage, a finding corroborated by the results of an analysis *in vivo*. To our best knowledge, this is the first study showing the implication of SMN during the progression of OA, shedding light on a novel cellular component of the disease that might allow to open new avenues of research on the onset of OA and to identify alternative, potent targets for therapy.

Regarding the possible roles played by SMN in OA, it is interesting to note that beside its housekeeping functions, SMN is a molecule essential for cell survival [21], displaying anti-apoptotic properties [23] possibly *via* direct interactions with Bcl-2 and p53 [40, 41], and having a key influence on transcriptional and post-transcriptional gene regulation [24, 25]. As a matter of fact, several lines of evidence have demonstrated the significance of cell death [12] and transcriptional regulation [26, 27] during the course of OA. The details of the implication of SMN in these mechanisms during OA remain to be elucidated. A comprehensive analysis in experimental systems of SMN inhibition in OA cartilage [20] or of overexpression in normal cartilage [19] may provide insights into the putative functions of SMN in this disorder and address the question whether SMN up-regulation is a protective response or is causally involved in the pathogenesis of OA.

Interestingly, SMN has been originally identified as the key determinant of spinal muscular atrophy (SMA) [42], a single inherited neuromuscular disorder characterized by the degeneration of spinal motor neurons leading to muscular paralysis with muscular atrophy [43]. Spinal muscular atrophy is linked to recessive mutations in the *smn* gene [44, 45], showing decreased SMN concentrations in the spinal cord, skeletal muscle, liver and fibroblasts of

SMA patients and a strong correlation between the disease severity and the SMN levels [34, 46]. It is noteworthy that we observed an up-regulation of cartilage SMN during OA whereas a dramatic reduction was demonstrated in SMA. While SMA has been identified as a single disorder linked to recessive mutations in the *smn* gene, OA represents a complex disease with multiple aetiologies (genetic background, ageing, trauma, obesity, stress environment). It is likely that the causative mechanisms regulating *smn* expression in these two pathologies are different. The results of future analyses as those described above (SMN blockade *versus* overexpression) might also help to better understand the divergence in the SMN profiles between OA and SMA. Taken together, the present findings describe SMN as a novel cellular component of the pathogenesis of OA that may provide new targets for therapy of this widespread, incurable disorder.

Acknowledgements

This work was supported by a grant from the German Osteoarthritis Foundation (*Deutsche Arthrose-Hilfe* grant P64-A234-Kohn-EP2-cucc2-sonder-ko-9k-2004-06 to MC and HM). The authors thank Mr. David Zurakowski (Children's Hospital, Orthopaedic Surgery and Biostatistics, Harvard Medical School, Boston, Massachusetts, USA) for support with the statistical analyses and Ms. Tanja Thurn for technical assistance.

Conflicts of interest

The authors have no conflict of interest.

Author contribution

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Cucchiariini had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MC: designed the research study; MC, HM: performed the research; MC, HM, EFT: analysed the data; MC: wrote the paper.

References

- Loeser RF, Goldring SR, Scanzello CR, *et al.* Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum.* 2012; 64: 1697–707.
- Poole AR. An introduction to the pathophysiology of osteoarthritis. *Front Biosci.* 1999; 4: D662–70.
- Goldring MB, Goldring SR. Osteoarthritis. *J Cell Physiol.* 2007; 213: 626–34.
- Lotz M, Loeser RF. Effects of aging on articular cartilage homeostasis. *Bone.* 2012; 51: 241–8.
- Loughlin J. Genetics of osteoarthritis. *Curr Opin Rheumatol.* 2011; 23: 479–83.
- Sandell LJ. Etiology of osteoarthritis: genetics and synovial joint development. *Nat Rev Rheumatol.* 2012; 8: 77–89.
- Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol.* 2011; 23: 471–8.
- Kapoor M, Martel-Pelletier J, Lajeunesse D, *et al.* Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. *Nat Rev Rheumatol.* 2011; 7: 33–42.
- Goldring MB, Marcu KB. Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis. *Trends Mol Med.* 2012; 18: 109–18.
- Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. *Arthritis Res.* 2001; 3: 107–13.

11. **Goldring MB.** The role of the chondrocyte in osteoarthritis. *Arthritis Rheum.* 2000; 43: 1916–26.
12. **Aigner T, Soder S, Gebhard PM, et al.** Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis-structure, chaos and senescence. *Nat Clin Pract Rheumatol.* 2007; 3: 391–9.
13. **Kraus VB, Burnett B, Coindreau J, et al.** Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. *Osteoarthritis Cartilage.* 2011; 19: 515–42.
14. **Patra D, Sandell LJ.** Recent advances in biomarkers in osteoarthritis. *Curr Opin Rheumatol.* 2011; 23: 465–70.
15. **Roach HI, Aigner T, Soder S, et al.** Pathobiology of osteoarthritis: pathomechanisms and potential therapeutic targets. *Curr Drug Targets.* 2007; 8: 271–82.
16. **van den Berg WB.** Osteoarthritis year 2010 in review: pathomechanisms. *Osteoarthritis Cartilage.* 2011; 19: 338–41.
17. **van der Kraan PM.** Osteoarthritis year 2012 in review: biology. *Osteoarthritis Cartilage.* 2012; 20: 1447–50.
18. **Wan L, Ottinger E, Cho S, et al.** Inactivation of the SMN complex by oxidative stress. *Mol Cell.* 2008; 31: 244–54.
19. **Zou T, Ilangoan R, Yu F, et al.** SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity. *Biochem Biophys Res Commun.* 2007; 364: 850–5.
20. **Zou T, Yang X, Pan D, et al.** SMN deficiency reduces cellular ability to form stress granules, sensitizing cells to stress. *Cell Mol Neurobiol.* 2011; 31: 541–50.
21. **Schrank B, Gotz R, Gunnarsen JM, et al.** Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. *Proc Natl Acad Sci USA.* 1997; 94: 9920–5.
22. **Fischer U, Liu Q, Dreyfuss G.** The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. *Cell.* 1997; 90: 1023–9.
23. **Kerr DA, Nery JP, Traystman RJ, et al.** Survival motor neuron protein modulates neuron-specific apoptosis. *Proc Natl Acad Sci USA.* 2000; 97: 13312–7.
24. **Pellizzoni L, Charroux B, Rappsilber J, et al.** A functional interaction between the survival motor neuron complex and RNA polymerase II. *J Cell Biol.* 2001; 152: 75–85.
25. **Strasswimmer J, Lorson CL, Breiding DE, et al.** Identification of survival motor neuron as a transcriptional activator-binding protein. *Hum Mol Genet.* 1999; 8: 1219–26.
26. **Drissi H, Zuscik M, Rosier R, et al.** Transcriptional regulation of chondrocyte maturation: potential involvement of transcription factors in OA pathogenesis. *Mol Aspects Med.* 2005; 26: 169–79.
27. **Goldring MB.** Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis. *Ther Adv Musculoskelet Dis.* 2012; 4: 269–85.
28. **Cucchiariini M, Thurn T, Weimer A, et al.** Restoration of the extracellular matrix in human osteoarthritic articular cartilage by overexpression of the transcription factor SOX9. *Arthritis Rheum.* 2007; 56: 158–67.
29. **Yoshioka M, Coutts RD, Amiel D, et al.** Characterization of a model of osteoarthritis in the rabbit knee. *Osteoarthritis Cartilage.* 1996; 4: 87–98.
30. **Mankin HJ, Dorfman H, Lippiello L, et al.** Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data. *J Bone Joint Surg Am.* 1971; 53: 523–37.
31. **Kolb SJ, Gubitz AK, Olszewski RF Jr, et al.** A novel cell immunoassay to measure survival of motor neurons protein in blood cells. *BMC Neurol.* 2006; 6: 6–10.
32. **Cucchiariini M, Ekici M, Schetting S, et al.** Metabolic activities and chondrogenic differentiation of human mesenchymal stem cells following recombinant adeno-associated virus-mediated gene transfer and overexpression of fibroblast growth factor 2. *Tissue Eng Part A.* 2011; 17: 1921–33.
33. **Simard LR, Belanger MC, Morissette S, et al.** Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. *Neurology.* 2007; 68: 451–6.
34. **Covert DD, Le TT, McAndrew PE, et al.** The survival motor neuron protein in spinal muscular atrophy. *Hum Mol Genet.* 1997; 6: 1205–14.
35. **Francis JW, Sandrock AW, Bhide PG, et al.** Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues. *Proc Natl Acad Sci USA.* 1998; 95: 6492–7.
36. **La Bella V, Kallenbach S, Pettmann B.** Post-translational modifications in the survival motor neuron protein. *Biochem Biophys Res Commun.* 2004; 324: 288–93.
37. **Baron-Delage S, Abadie A, Echaniz-Laguna A, et al.** Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. *Mol Med.* 2000; 6: 957–68.
38. **Lunke S, El-Osta A.** The emerging role of epigenetic modifications and chromatin remodeling in spinal muscular atrophy. *J Neurochem.* 2009; 109: 1557–69.
39. **Roach HI, Aigner T.** DNA methylation in osteoarthritic chondrocytes: a new molecular target. *Osteoarthritis Cartilage.* 2007; 15: 128–37.
40. **Iwahashi H, Eguchi Y, Yasuhara N, et al.** Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. *Nature.* 1997; 390: 413–7.
41. **Young PJ, Day PM, Zhou J, et al.** A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. *J Biol Chem.* 2002; 277: 2852–9.
42. **Lefebvre S, Burglen L, Reboullet S, et al.** Identification and characterization of a spinal muscular atrophy-determining gene. *Cell.* 1995; 80: 155–65.
43. **Pearn J.** Classification of spinal muscular atrophies. *Lancet.* 1980; 1: 919–22.
44. **Melki J, Lefebvre S, Burglen L, et al.** De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. *Science.* 1994; 264: 1474–7.
45. **Thompson TG, DiDonato CJ, Simard LR, et al.** A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients. *Nat Genet.* 1995; 9: 56–62.
46. **Lefebvre S, Burlet P, Liu Q, et al.** Correlation between severity and SMN protein level in spinal muscular atrophy. *Nat Genet.* 1997; 16: 265–9.